{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T22:49:41Z","timestamp":1784328581118,"version":"3.55.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2014,6,1]],"date-time":"2014-06-01T00:00:00Z","timestamp":1401580800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["diabetesresearchclinicalpractice.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Research and Clinical Practice"],"published-print":{"date-parts":[[2014,6]]},"DOI":"10.1016\/j.diabres.2013.12.033","type":"journal-article","created":{"date-parts":[[2014,1,14]],"date-time":"2014-01-14T12:34:18Z","timestamp":1389702858000},"page":"401-409","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Lack of effect of colesevelam HCl on the single-dose pharmacokinetics of aspirin, atenolol, enalapril, phenytoin, rosiglitazone, and sitagliptin"],"prefix":"10.1016","volume":"104","author":[{"given":"Ling","family":"He","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prachi","family":"Wickremasingha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanne","family":"Mendell-Harary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas","family":"Wight","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.diabres.2013.12.033_bib0005","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1097\/MJT.0b013e31815a69fc","article-title":"The \u2018forgotten\u2019 bile acid sequestrants: is now a good time to remember?","volume":"14","author":"Bays","year":"2007","journal-title":"Am J Ther"},{"key":"10.1016\/j.diabres.2013.12.033_bib0010","series-title":"Welchol [package insert]","year":"2012"},{"key":"10.1016\/j.diabres.2013.12.033_bib0015","doi-asserted-by":"crossref","first-page":"355","DOI":"10.2165\/00002018-199819050-00003","article-title":"Drug interactions of lipid-altering drugs","volume":"19","author":"Bays","year":"1998","journal-title":"Drug Saf"},{"key":"10.1016\/j.diabres.2013.12.033_bib0020","first-page":"708","article-title":"In vitro comparison of bile acid binding to colesevelam HCl and other bile acid sequestrants","volume":"41","author":"Braunlin","year":"2000","journal-title":"Polymer Prepr"},{"issue":"6A","key":"10.1016\/j.diabres.2013.12.033_bib0025","doi-asserted-by":"crossref","first-page":"47C","DOI":"10.1016\/j.amjcard.2006.11.022","article-title":"Safety considerations with gastrointestinally active lipid-lowering drugs","volume":"99","author":"Jacobson","year":"2007","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.diabres.2013.12.033_bib0030","doi-asserted-by":"crossref","first-page":"197","DOI":"10.2147\/tcrm.2007.3.1.197","article-title":"Polypharmacy in elderly patients at discharge from the acute care hospital","volume":"3","author":"Corsonello","year":"2007","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.diabres.2013.12.033_bib0035","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.2337\/diacare.26.5.1408","article-title":"Polypharmacy and medication adherence in patients with type 2 diabetes","volume":"26","author":"Grant","year":"2003","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2013.12.033_bib0040","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1185\/030079907X199600","article-title":"The complexity of medication regimens and test ordering for patients with diabetes from 1995 to 2003","volume":"23","author":"Huang","year":"2007","journal-title":"Curr Med Res Opin"},{"issue":"Suppl 1","key":"10.1016\/j.diabres.2013.12.033_bib0045","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.2337\/dc13-S011","article-title":"Standards of medical care in diabetes\u20142013","volume":"36","author":"American Diabetes Association","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2013.12.033_bib0050","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/S0735-6757(96)90147-3","article-title":"Drug\u2013drug and drug\u2013disease interactions in the ED: analysis of a high-risk population","volume":"14","author":"Goldberg","year":"1996","journal-title":"Am J Emerg Med"},{"key":"10.1016\/j.diabres.2013.12.033_bib0055","doi-asserted-by":"crossref","first-page":"911","DOI":"10.2165\/00002018-200730100-00009","article-title":"The relationship between number of drugs and potential drug\u2013drug interactions in the elderly: a study of over 600,000 elderly patients from the Swedish Prescribed Drug Register","volume":"30","author":"Johnell","year":"2007","journal-title":"Drug Saf"},{"key":"10.1016\/j.diabres.2013.12.033_bib0060","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S0140-6736(75)90962-9","article-title":"Serum-phenytoin levels in management of epilepsy","volume":"306","author":"Richens","year":"1975","journal-title":"Lancet"},{"key":"10.1016\/j.diabres.2013.12.033_bib0065","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1177\/0091270009340783","article-title":"Quantitative structure-property relationships modeling to predict in vitro and in vivo binding of drugs to the bile sequestrant, colesevelam (Welchol)","volume":"49","author":"Walker","year":"2009","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.diabres.2013.12.033_bib0070","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1172\/JCI110576","article-title":"Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects","volume":"69","author":"Patrignani","year":"1982","journal-title":"J Clin Invest"},{"key":"10.1016\/j.diabres.2013.12.033_bib0075","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1002\/j.1552-4604.1995.tb04044.x","article-title":"Variability in the pharmacokinetics and pharmacodynamics of low dose aspirin in healthy male volunteers","volume":"35","author":"Benedek","year":"1995","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.diabres.2013.12.033_bib0080","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1111\/j.1742-7843.2006.pto_379.x","article-title":"Effect of rifampicin on the pharmacokinetics of atenolol","volume":"98","author":"Lilja","year":"2006","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"10.1016\/j.diabres.2013.12.033_bib0085","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1002\/bdd.2510120606","article-title":"Pharmacokinetic comparison of a combination tablet of enalapril and hydrochlorothiazide with enalapril and hydrochlorothiazide tablets administered together and separately","volume":"12","author":"Howes","year":"1991","journal-title":"Biopharm Drug Dispos"},{"key":"10.1016\/j.diabres.2013.12.033_bib0090","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s002280050592","article-title":"Systemic exposure to rosiglitazone is unaltered by food","volume":"55","author":"Freed","year":"1999","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.diabres.2013.12.033_bib0095","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1177\/0091270006289850","article-title":"Pharmacokinetics and pharmacodynamic effects of the oral DPP-4 inhibitor sitagliptin in middle-aged obese subjects","volume":"46","author":"Herman","year":"2006","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.diabres.2013.12.033_bib0100","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1185\/030079908X280446","article-title":"Colesevelam hydrochloride in clinical practice: a new approach in the treatment of hypercholesterolaemia","volume":"24","author":"Florentin","year":"2008","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.diabres.2013.12.033_bib0105","series-title":"Cholestyramine for oral suspension USP [package insert]","year":"2012"},{"key":"10.1016\/j.diabres.2013.12.033_bib0110","doi-asserted-by":"crossref","first-page":"60","DOI":"10.3181\/00379727-120-30443","article-title":"The interaction between cholestyramine and drugs","volume":"120","author":"Gallo","year":"1965","journal-title":"Proc Soc Exp Biol Med"},{"key":"10.1016\/j.diabres.2013.12.033_bib0115","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/j.1365-2125.1978.tb01651.x","article-title":"Enhanced elimination of warfarin during treatment with cholestyramine","volume":"5","author":"J\u00e4hnchen","year":"1978","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.diabres.2013.12.033_bib0120","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1007\/BF00561136","article-title":"Effect of cholestyramine on the gastrointestinal absorption of phenprocoumon and acetylosalicylic acid in man","volume":"4","author":"Hahn","year":"1972","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.diabres.2013.12.033_bib0125","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/clpt.1986.48","article-title":"Influence of time intervals for cholestyramine dosing on the absorption of hydrochlorothiazide","volume":"39","author":"Hunninghake","year":"1986","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.diabres.2013.12.033_bib0130","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/j.1365-2125.1984.tb02473.x","article-title":"Effects of cholestyramine and colestipol on the plasma concentrations of propranolol","volume":"18","author":"Hibbard","year":"1984","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.diabres.2013.12.033_bib0135","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1001\/jama.1969.03160100047012","article-title":"The influence of cholestyramine on thyroxine absorption","volume":"208","author":"Northcutt","year":"1969","journal-title":"JAMA"},{"key":"10.1016\/j.diabres.2013.12.033_bib0140","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1161\/01.CIR.58.1.164","article-title":"Decreased bioavailability of digoxin due to hypocholesterolemic interventions","volume":"58","author":"Brown","year":"1978","journal-title":"Circulation"},{"key":"10.1016\/j.diabres.2013.12.033_bib0145","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1248\/bpb.19.1231","article-title":"Drug interaction between simvastatin and cholestyramine in vitro and in vivo","volume":"19","author":"Nakai","year":"1996","journal-title":"Biol Pharm Bull"},{"key":"10.1016\/j.diabres.2013.12.033_bib0150","first-page":"208","article-title":"Effect of cholestyramine resin on single dose valproate pharmacokinetics","volume":"34","author":"Malloy","year":"1996","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1016\/j.diabres.2013.12.033_bib0155","first-page":"286","article-title":"Influence of cholestyramine resin administration on single dose sulindac pharmacokinetics","volume":"32","author":"Malloy","year":"1994","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1016\/j.diabres.2013.12.033_bib0160","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1002\/bdd.2510050106","article-title":"Interaction of naproxen with cholestyramine","volume":"5","author":"Calvo","year":"1984","journal-title":"Biopharm Drug Dispos"},{"key":"10.1016\/j.diabres.2013.12.033_bib0165","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1111\/j.0954-6820.1978.tb08481.x","article-title":"Interaction by cholestyramine on the uptake of hydrocortisone in the gastrointestinal tract","volume":"204","author":"Johansson","year":"1978","journal-title":"Acta Med Scand"},{"key":"10.1016\/j.diabres.2013.12.033_bib0170","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1080\/00498250600839369","article-title":"Influence of cholestyramine on the pharmacokinetics of rosiglitazone and its metabolite, desmethylrosiglitazone, after oral and intravenous dosing of rosiglitazone: impact on oral bioavailability, absorption, and metabolic disposition in rats","volume":"36","author":"Muzeeb","year":"2006","journal-title":"Xenobiotica"},{"key":"10.1016\/j.diabres.2013.12.033_bib0175","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1111\/j.1365-2125.1990.tb03843.x","article-title":"The effect of cholestyramine and activated charcoal on glipizide absorption","volume":"30","author":"Kivist\u00f6","year":"1990","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.diabres.2013.12.033_bib0180","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1097\/00007691-199208000-00014","article-title":"Interaction of tricyclic antidepressants with cholestyramine in vitro","volume":"14","author":"Bailey","year":"1992","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.diabres.2013.12.033_bib0185","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1177\/0091270009349378","article-title":"Effect of the bile acid sequestrant colesevelam on the pharmacokinetics of pioglitazone, repaglinide, estrogen estradiol, norethindrone, levothyroxine, and glyburide","volume":"50","author":"Brown","year":"2010","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.diabres.2013.12.033_bib0190","doi-asserted-by":"crossref","first-page":"943","DOI":"10.2165\/00003088-200443130-00006","article-title":"Effect of colesevelam HCl on single-dose fenofibrate pharmacokinetics","volume":"43","author":"Jones","year":"2004","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.diabres.2013.12.033_bib0195","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1345\/aph.1A144","article-title":"Effect of colesevelam on lovastatin pharmacokinetics","volume":"36","author":"Donovan","year":"2002","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.diabres.2013.12.033_bib0200","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1023\/A:1007831418308","article-title":"Drug interactions with colesevelam hydrochloride, a novel, potent lipid-lowering agent","volume":"14","author":"Donovan","year":"2000","journal-title":"Cardiovasc Drugs Ther"}],"container-title":["Diabetes Research and Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822713004671?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822713004671?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,7]],"date-time":"2018-10-07T10:21:12Z","timestamp":1538907672000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168822713004671"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6]]},"references-count":40,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,6]]}},"alternative-id":["S0168822713004671"],"URL":"https:\/\/doi.org\/10.1016\/j.diabres.2013.12.033","relation":{},"ISSN":["0168-8227"],"issn-type":[{"value":"0168-8227","type":"print"}],"subject":[],"published":{"date-parts":[[2014,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lack of effect of colesevelam HCl on the single-dose pharmacokinetics of aspirin, atenolol, enalapril, phenytoin, rosiglitazone, and sitagliptin","name":"articletitle","label":"Article Title"},{"value":"Diabetes Research and Clinical Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diabres.2013.12.033","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}